NABI STARTS OVER WITH STAPHVAX

Nabi Biopharmaceuticals Inc. said Tuesday it will restart development of its experimental vaccine for staph infections and will look for a partner to help it take the drug through new clinical trials. Nabi halted the development of StaphVAX in November after the vaccine failed in large-scale clinical studies.
INS News